CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Material-Driven Therapeutics: Functional Nanomaterial Design Paradigms Revolutionizing Osteosarcoma Treatment.
Material-Driven Therapeutics: Functional Nanomaterial Design Paradigms Revolutionizing Osteosarcoma Treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
骨肉瘤(OS)是儿童和青少年中常见的原发性恶性骨肿瘤,自20世纪70年代以来,其治疗方案一直保持稳定,包括手术、化疗和放疗。虽然这些策略对局限性肿瘤有效,但对转移性或复发病例疗效有限。尽管新兴的免疫疗法(PD-1抑制剂、CAR-T 细胞疗法)显示出治疗潜力,但其临床效果仍受限于肿瘤的低免疫原性和免疫抑制微环境,导致缓解率不理想。该疾病的侵袭性及肺转移倾向导致预后不良,尽管治疗取得了进展,但五十年来生存率改善甚微,造成了重大的临床和社会经济挑战。纳米医学的最新发展为OS治疗优化提供了有前景的解决方案。本综述通过材料科学的视角,系统考察了纳米材料在OS治疗中的应用,分析了针对特定机制的干预措施,并重点介绍了过去五年的显著进展。我们批判性地评估了当前在提高疗效的同时降低毒性的策略,最终概述了临床转化的路径和关键挑战。该分析为开发下一代纳米治疗平台以解决OS管理中持续存在的局限性建立了框架。
Osteosarcoma (OS), a prevalent primary malignant bone tumor in children and adolescents, has maintained consistent treatment protocols since the 1970s combining surgery, chemotherapy, and radiotherapy. While effective for localized tumors, these strategies show limited efficacy against metastatic or recurrent cases. Although emerging immunotherapies (PD-1 inhibitors, CAR-T-cell therapy) demonstrate therapeutic potential, their clinical impact remains constrained by the tumor's low immunogenicity and immunosuppressive microenvironment, resulting in suboptimal response rates.
The disease's aggressive nature and propensity for pulmonary metastasis contribute to poor prognosis, with survival rates showing negligible improvement over five decades despite therapeutic advances, creating substantial clinical and socioeconomic challenges.
Recent developments in nanomedicine offer promising solutions for OS treatment optimization. This review systematically examines nanomaterial applications in OS therapy through a materials science lens, analyzing mechanism-specific interventions and highlighting notable advancements from the past five years.
We critically evaluate current strategies for enhancing therapeutic efficacy while reducing toxicity profiles, ultimately outlining translational pathways and key challenges in clinical adaptation. The analysis establishes a framework for developing next-generation nanotherapeutic platforms to address persistent limitations in OS management.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。